A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

Nature

Volumn 551, Issue 7681, 2017, Pages 517-520

  Luksza, Marta ^a   Riaz, Nadeem ^b   Makarov, Vladimir ^b   Balachandran, Vinod P ^b   Hellmann, Matthew D ^b,c   Solovyov, Alexander ^d   Rizvi, Naiyer A ^e   Merghoub, Taha ^b   Levine, Arnold J ^a   Chan, Timothy A ^b   Wolchok, Jedd D ^b   Greenbaum, Benjamin D ^d  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GILVETMAB; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PDCD1 PROTEIN, HUMAN; TUMOR ANTIGEN;

CANCER; CELLS AND CELL COMPONENTS; FITNESS; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOGEN; PEPTIDE; SURVIVAL; TUMOR;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; DISEASE DURATION; FITNESS; HUMAN; HYDROPHOBICITY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SOMATIC MUTATION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTATION; BIOLOGICAL MODEL; CELL CYCLE CHECKPOINT; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; LYMPHOCYTE ACTIVATION; MELANOMA; MOLECULAR EVOLUTION; PATHOLOGY; SURVIVAL ANALYSIS;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; COHORT STUDIES; CTLA-4 ANTIGEN; EVOLUTION, MOLECULAR; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA; MODELS, IMMUNOLOGICAL; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 85034865728     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature24473     Document Type: Article

References (40)

1. Topalian, S. L., Drake, C. G., Pardoll, D. M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
2. Schumacher, T. N., Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
3. Gubin, M. M., Artyomov, M. N., Mardis, E. R., Schreiber, R. D. Tumor neoantigens: Building a framework for personalized cancer immunotherapy. J. Clin. Invest. 125, 3413-3421 (2015).
4. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
5. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
6. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
7. Uksza, M., Lässig, M. A predictive fitness model for influenza. Nature 507, 57-61 (2014).
8. Wang, S. et al. Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell 160, 785-797 (2015).
9. Nourmohammad, A., Otwinowski, J., Plotkin, J. B. Host-pathogen coevolution and the emergence of broadly neutralizing antibodies in chronic infections. PLoS Genet. 12, e1006171 (2016).
10. Le, D. T. et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409-413 (2017).
11. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
12. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
13. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
14. De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K in myeloid cells. Nature 539, 443-447 (2016).
15. Ayers, M. et al. IFN-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930-2940 (2017).
16. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463-1469 (2016).
17. Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7, 264-276 (2017).
18. Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46, 315-326 (2017).
19. Andreatta, M., Nielsen, M. Gapped sequence alignment using artificial neural networks: Application to the MHC class I system. Bioinformatics 32, 511-517 (2016).
20. Vita, R. et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 43, D405-D412 (2015).
21. Murugan, A., Mora, T., Walczak, A. M., Callan, C. G. Jr. Statistical inference of the generation probability of T-cell receptors from sequence repertoires. Proc. Natl Acad. Sci. USA 109, 16161-16166 (2012).
22. Birnbaum, M. E. et al. Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157, 1073-1087 (2014).
23. Lehmann, J., Libchaber, A., Greenbaum, B. D. Fundamental amino acid mass distributions and entropy costs in proteomes. J. Theor. Biol. 410, 119-124 (2016).
24. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015).
25. Tanne, A. et al. Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells. Proc. Natl Acad. Sci. USA 112, 15154-15159 (2015).
26. Vétizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079-1084 (2015).
27. Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).
28. Stronen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337-1341 (2016).
29. Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749-1755 (2016).
30. Hofmann, L. et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer 60, 190-209 (2016).
31. Deshwar, A. G. et al. PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol. 16, 35 (2015).
32. Stormo, G. D. Modeling the specificity of protein-DNA interactions. Quant. Biol. 1, 115-130 (2013).
33. Yu, W. et al. Clonal deletion prunes but does not eliminate self-specific CD8+ T lymphocytes. Immunity 42, 929-941 (2015).
34. Legoux, F. P. et al. CD4+ T cell tolerance to tissue-restricted self antigens is mediated by antigen-specific regulatory T cells rather than deletion. Immunity 43, 896-908 (2015).
35. Paul, S. et al. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J. Immunol. 191, 5831-5839 (2013).
36. Mason, D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 19, 395-404 (1998).
37. Sewell, A. K. Why must T cells be cross-reactive Nat. Rev. Immunol. 12, 669-677 (2012).
38. Henikoff, S., Henikoff, J. G. Amino acid substitution matrices from protein blocks. Proc. Natl Acad. Sci. USA 89, 10915-10919 (1992).
39. Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453-457 (2015).
40. Nielsen, M., Lundegaard, C., Lund, O., Keşmir, C. The role of the proteasome in generating cytotoxic T-cell epitopes: Insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57, 33-41 (2005).